CLBT vs. OKTA, CYBR, DOCU, GEN, TWLO, SNAP, MDB, DT, DUOL, and YMM
Should you be buying Cellebrite DI stock or one of its competitors? The main competitors of Cellebrite DI include Okta (OKTA), CyberArk Software (CYBR), DocuSign (DOCU), Gen Digital (GEN), Twilio (TWLO), Snap (SNAP), MongoDB (MDB), Dynatrace (DT), Duolingo (DUOL), and Full Truck Alliance (YMM). These companies are all part of the "computer software" industry.
Cellebrite DI vs.
Cellebrite DI (NASDAQ:CLBT) and Okta (NASDAQ:OKTA) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
45.9% of Cellebrite DI shares are held by institutional investors. Comparatively, 86.6% of Okta shares are held by institutional investors. 5.7% of Cellebrite DI shares are held by insiders. Comparatively, 7.0% of Okta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cellebrite DI has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Okta has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Cellebrite DI presently has a consensus price target of $23.43, indicating a potential upside of 31.99%. Okta has a consensus price target of $116.09, indicating a potential upside of 27.03%. Given Cellebrite DI's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cellebrite DI is more favorable than Okta.
In the previous week, Okta had 21 more articles in the media than Cellebrite DI. MarketBeat recorded 30 mentions for Okta and 9 mentions for Cellebrite DI. Cellebrite DI's average media sentiment score of 0.97 beat Okta's score of 0.95 indicating that Cellebrite DI is being referred to more favorably in the media.
Okta has a net margin of -1.54% compared to Cellebrite DI's net margin of -70.54%. Cellebrite DI's return on equity of 58.70% beat Okta's return on equity.
Cellebrite DI has higher earnings, but lower revenue than Okta. Cellebrite DI is trading at a lower price-to-earnings ratio than Okta, indicating that it is currently the more affordable of the two stocks.
Okta received 536 more outperform votes than Cellebrite DI when rated by MarketBeat users. However, 67.65% of users gave Cellebrite DI an outperform vote while only 58.20% of users gave Okta an outperform vote.
Summary
Cellebrite DI beats Okta on 10 of the 19 factors compared between the two stocks.
Get Cellebrite DI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLBT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellebrite DI Competitors List
Related Companies and Tools
This page (NASDAQ:CLBT) was last updated on 4/9/2025 by MarketBeat.com Staff
